Willow Biosciences Inc. Completes Sale of Its Operating Subsidiary and Management Transition

Willow Biosciences Inc. Completes Sale of Operating Subsidiary

Willow Biosciences Inc. has officially completed the sale of its wholly-owned subsidiary, Epimeron USA, Inc., to Mycofeast Ltd., a private entity based in the UK. This transaction marks a pivotal moment in the company’s history as it seeks to navigate new opportunities and establish fresh leadership dynamics.

Transaction Overview

As announced on April 30, 2025, the sale was executed under a share purchase agreement formulated on March 14, 2025. The total consideration for the transaction amounts to $2.76 million, which is subject to financial adjustments. Importantly, a portion of this payment, approximately $275,975, has been placed in escrow until mid-September 2025. This amount will cover any claims for indemnity and any required post-closing price adjustments, highlighting the complexities involved in corporate financial dealings.

With this move, Willow Biosciences aims to apply part of the proceeds to reduce its debts, demonstrating its commitment to strengthening the company’s balance sheet and overall financial health. The remainder of the funds will be held while the company evaluates its cash flow needs and considers potential new opportunities, all in a bid to enhance value for its shareholders.

Management Changes

As integral to the completion of this sale, there have been significant shifts in the company’s management. Dr. Chris Savile, the company’s President and CEO, along with Dr. Trish Choudhary, Senior Vice President of Research and Development, have both resigned to pursue roles with Mycofeast Ltd. in the aftermath of the acquisition. Their exit represents a transition for the company, which will now be guided in part by newly appointed Interim Chief Executive Officer, Travis Doupe, who has served as Chief Financial Officer.

The board of directors has expressed immense gratitude to Dr. Savile and Dr. Choudhary for their dedicated service and contributions to the company, wishing them success in their new endeavors. This managerial restructuring is reflective of Willow Biosciences’ strategy to adapt and respond to the evolving market while reinforcing its leadership framework.

Future Directions

Moving forward, Willow Biosciences is optimistic about harnessing the potential from this transaction. The company’s leadership is prepared to evaluate various avenues for investment that could contribute to growth and sustainability. The management has indicated that the insights available via the Information Circular, distributed on March 26, 2025, will offer further details and clarity regarding the transaction and the path ahead.

As the corporation transitions into this new era, it remains committed to maintaining transparency with its stakeholders and ensuring all actions align with maximizing shareholder value. The forward-looking statements issued by the company are accompanied by a reminder of the inherent risks involved in such significant changes, underscoring the complex landscape of corporate operations.

In summary, the completion of the sale of Epimeron USA, Inc. brings about new management strategies, financial realignment, and a rejuvenated focus on future opportunities, marking an important transitional phase for Willow Biosciences Inc.